Avalo Therapeutics Files 8-K
Ticker: AVTX · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, company-information
Related Tickers: AVLO
TL;DR
AVLO filed an 8-K on 10/29/25. Check for updates.
AI Summary
Avalo Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting other events and financial statements. The company, formerly known as Cerecor Inc. until November 2, 2011, is incorporated in Delaware and headquartered in Wayne, Pennsylvania.
Why It Matters
This filing indicates Avalo Therapeutics is making a regulatory submission, which could contain updates on financial status or significant business events.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on events that have already occurred or are standard financial reporting.
Key Numbers
- 001-37590 — SEC File Number (Identifies the company's filing with the SEC)
- 45-0705648 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- October 29, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Wayne, Pennsylvania (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Avalo Therapeutics in this 8-K?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
When did Avalo Therapeutics change its name from Cerecor Inc.?
Avalo Therapeutics, Inc. was formerly known as Cerecor Inc. until November 2, 2011.
What is the principal executive office address for Avalo Therapeutics?
The principal executive offices are located at 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087.
What is the SIC code for Avalo Therapeutics?
The Standard Industrial Classification (SIC) code for Avalo Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Avalo Therapeutics?
The fiscal year end for Avalo Therapeutics is December 31 (1231).
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-10-29 07:04:33
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20251029.htm (8-K) — 25KB
- ex-991lotusenrollment.htm (EX-99.1) — 14KB
- avalologoa.jpg (GRAPHIC) — 8KB
- 0001534120-25-000013.txt ( ) — 191KB
- avtx-20251029.xsd (EX-101.SCH) — 2KB
- avtx-20251029_def.xml (EX-101.DEF) — 14KB
- avtx-20251029_lab.xml (EX-101.LAB) — 24KB
- avtx-20251029_pre.xml (EX-101.PRE) — 15KB
- avtx-20251029_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 29, 2025, Avalo Therapeutics, Inc. issued a press release announcing the completion of enrollment of its Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release, dated October 29, 2025. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: October 29, 2025 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2